Specifically in breast cancer, previous research has shown that overexpression of COX-2 is observed in nearly 60% of invasive breast cancer, while barely detectable in most normal tissues, thus, it may be an early event in mammary tumorigenesis (14–16). This evidence concerns the gene PTGS2 and breast carcinoma.